In 2012, Pfizer’s Deal-Makers Seek Strategic Fit, Financial Discipline, Collaborative Risk-Sharing
This article was originally published in The Pink Sheet Daily
Executive Summary
The Big Pharma has the global scale and reach it needs, but will fill in gaps with deals in which it can add “a lot of” scientific value and “incremental” commercial value, says Pfizer’s EVP-Business Development Kristin Peck.